1.
Oncoimmunology
; 6(2): e1265721, 2017.
Article
in English
| MEDLINE
| ID: mdl-28344875
ABSTRACT
The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic lymphocytes using a virally encoded immune evasion protein and an IL-2 mutant that avoids off-target side effects such as activation of regulatory T cells and vascular endothelium.